US20230157863A1 - Intrauterine device with controlled copper ion elution - Google Patents
Intrauterine device with controlled copper ion elution Download PDFInfo
- Publication number
- US20230157863A1 US20230157863A1 US18/158,149 US202318158149A US2023157863A1 US 20230157863 A1 US20230157863 A1 US 20230157863A1 US 202318158149 A US202318158149 A US 202318158149A US 2023157863 A1 US2023157863 A1 US 2023157863A1
- Authority
- US
- United States
- Prior art keywords
- copper
- frame
- metal
- iud
- shape memory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000010828 elution Methods 0.000 title claims abstract description 18
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 title description 24
- 229910001431 copper ion Inorganic materials 0.000 title description 24
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 141
- 229910052802 copper Inorganic materials 0.000 claims abstract description 104
- 239000010949 copper Substances 0.000 claims abstract description 104
- 229910052751 metal Inorganic materials 0.000 claims abstract description 59
- 239000002184 metal Substances 0.000 claims abstract description 59
- 239000000463 material Substances 0.000 claims abstract description 20
- 239000003433 contraceptive agent Substances 0.000 claims abstract description 12
- 230000002254 contraceptive effect Effects 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 9
- 238000007493 shaping process Methods 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 26
- 229910001000 nickel titanium Inorganic materials 0.000 description 26
- 230000000694 effects Effects 0.000 description 19
- 230000007797 corrosion Effects 0.000 description 15
- 238000005260 corrosion Methods 0.000 description 15
- 239000012530 fluid Substances 0.000 description 13
- 150000002739 metals Chemical class 0.000 description 13
- 239000003984 copper intrauterine device Substances 0.000 description 12
- 230000010287 polarization Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000004291 uterus Anatomy 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 8
- 230000003054 hormonal effect Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000011324 bead Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229960004400 levonorgestrel Drugs 0.000 description 4
- 230000002175 menstrual effect Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 229910045601 alloy Inorganic materials 0.000 description 3
- 239000000956 alloy Substances 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000003756 cervix mucus Anatomy 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000007769 metal material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 229910000531 Co alloy Inorganic materials 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 208000000450 Pelvic Pain Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 229920005570 flexible polymer Polymers 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 208000007106 menorrhagia Diseases 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 230000019100 sperm motility Effects 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229910052715 tantalum Inorganic materials 0.000 description 2
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 206010006313 Breast tenderness Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000784732 Lycaena phlaeas Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012993 chemical processing Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000037416 cystogenesis Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- -1 levonorgestrel) Chemical compound 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940110234 mirena Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000009972 noncorrosive effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
- A61F6/142—Wirelike structures, e.g. loops, rings, spirals
- A61F6/144—Wirelike structures, e.g. loops, rings, spirals with T-configuration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
- A61F6/18—Inserters or removers ; Apparatus for loading an intra-uterine device into an insertion tube
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49826—Assembling or joining
Definitions
- the present invention relates to medical devices. More specifically, the invention relates to intrauterine devices for contraception.
- IUD intrauterine device
- T-shaped device containing copper or hormone (e.g., levonorgestrel), which is inserted into the uterus to provide long-acting, reversible contraception.
- hormone e.g., levonorgestrel
- IUDs are the most widely used form of reversible contraception, with more than 180 million users worldwide.
- IUDs typically are one of two types—copper or hormonal.
- the copper ion release characteristics of a typical plastic-frame IUD are strictly governed by the amount, preparation and configuration of the copper itself.
- increased effectiveness typically means increased amounts of copper on the IUD, and increased amounts of copper typically lead to increased side effects, primarily increased menstrual and intermenstrual bleeding, and increased pelvic pain. Balancing effectiveness with minimization of side effects has been a continuing challenge for making copper IUDs.
- copper IUD ability to provide emergency contraception up to five days after unprotected sex. It is generally known as the most effective form of emergency contraception available. Another advantage is that it contains no hormones, so it can be used while breast feeding, and fertility returns quickly after removal. Lastly, copper IUDs have been shown to be clinically effective for up to 10 years of continuous use. Disadvantages include the possibility of heavier menstrual periods and more painful menstrual cramping in some women.
- a hormonal IUD such as the Mirena® Levonorgestrel-releasing intrauterine system (www.mirena-us.com), uses the controlled release of a hormonal contraceptive such as Levonorgestrel (a progestin).
- the hormonal contraceptive released from a hormonal IUD prevents ovulation from occurring.
- the hormone also thickens the cervical mucus so that sperm cannot reach the fallopian tubes.
- Hormonal IUDs can typically be implanted for up to 5 years.
- Hormonal IUDs do not increase bleeding as copper-containing IUDs do. Instead, they can often reduce menstrual bleeding or prevent menstruation altogether, and thus they are sometimes used as a treatment for menorrhagia (heavy menstrual bleeding). Hormonal IUDs have common side effects, however. The most common side effects with levonorgestrel IUDs are hormone-related effects, such as headaches, nausea, breast tenderness, depression and cyst formation.
- copper IUDs are preferable for many women. Although currently available copper IUDs are very effective, it would still be advantageous to have improved copper IUDs. For example, it would be advantageous to have copper IUDs that were very effective but had minimal side effects.
- an improved copper IUD Disclosed herein are various embodiments of an improved copper IUD.
- the described embodiments provide an IUD with a desirable (or “controlled”) release rate of copper ions.
- Different embodiments may be configured with different copper ion release rates. For example, a particular copper ion release rate may be identified to provide a desired balance between IUD effectiveness and reduced side effects, compared to currently available devices.
- an intrauterine contraceptive device may include a frame comprising a first metal having a first galvanic potential and at least one metallic member coupled with the frame, the at least one metallic member comprising a second metal having a second galvanic potential different from the first galvanic potential.
- the first galvanic potential may be more anodic than the second galvanic potential.
- the first galvanic potential may be more cathodic than the second galvanic potential.
- a method of manufacturing an IUD for contraception that has a desired copper elution rate may involve: selecting an elongate shape memory member comprising a first metal having a first galvanic potential; selecting at least one attachment member comprising a second metal having a second galvanic potential that is different from the first galvanic potential; attaching the attachment member(s) to the shape memory member; and shaping the shape memory member to form a frame of the intrauterine contraceptive device.
- the first metal and the second metal may be specifically selected as materials for the shape memory member and the at least one attachment member, in order to achieve the desired copper elution rate.
- FIG. 1 is a front view of a prior art, T-shaped, copper IUD with a plastic support structure
- FIG. 2 is a bar graph illustrating a galvanic series for a number of common metals and alloys
- FIG. 3 is a front view of a copper IUD with a metal frame, according to one embodiment
- the mechanism of action of a copper IUD is essentially a predictable electrochemical process of corrosion, driven by the IUD's immersion in the uterine fluid. Over time, the copper elements of the IUD (copper wires, beads, tubes, or the like) corrode and release copper ions. For a given IUD, the copper ion release rate can be measured using standard laboratory tests in simulated uterine fluid (SUF). Typically, the release rate is governed by the surface area and volume of copper, the chemistry (especially pH) of the SUF, and the specific composition and surface properties of the copper elements. In currently available IUDs, the primary driver influencing the copper release rate is the amount of exposed copper surface area. In other words, to achieve a higher copper ion release rate, an IUD would typically have an increased copper surface area, which generally means the IUD will contain more copper overall.
- the primary driver influencing the copper release rate is the amount of exposed copper surface area. In other words, to achieve a higher copper ion release rate, an IUD would typically have an increased copper
- the IUD 10 includes a frame 12 , copper sleeves 14 disposed around the frame 12 in three areas, and a retrieval string 16 .
- the frame 12 is typically made of a flexible polymer and is often T-shaped for positioning in the uterus. Since typical polymers are not electrochemically active, they do not influence the ion release rate of the copper elements 14 . Therefore, the copper ion release characteristics are strictly governed by the amount of surface area of the copper sleeves 14 themselves.
- Galvanic corrosion is an electrochemical process in which one metal corrodes preferentially to another when both metals are in electrical contact and immersed in an electrolyte.
- the strength of this electrical potential between two metals or alloys is called the galvanic potential.
- the galvanic reaction can be exploited for positive benefit.
- a galvanic potential between dissimilar metals can be used in primary batteries to generate an electrical voltage.
- the measured voltage is representative of the transfer of charged metal ions from one of the metals (the anode) to the other (the cathode). The stronger the galvanic effect between the two metals, the higher the transfer rate of ions from the anode to the cathode.
- a galvanic series an example of which is illustrated in FIG. 2 .
- metals are ranked by the electrical potential they develop in a given electrolyte against a standard reference electrode— i.e., their galvanic potential versus the reference electrode.
- the relative position of two metals on such a series determines which metal will be the anode and which will be the cathode (if they are put in contact in an appropriate electrolyte).
- the magnitude of the distance between the two metals on the galvanic series will determine the strength of the galvanic potential between them.
- a specific galvanic series can be determined for any metals or alloys of interest, tested in a specific electrolyte (e.g., SUF) at an appropriate pH.
- an IUD 20 may include a metal frame 22 (or “shape memory member”), multiple copper sleeves 24 (or “copper elements”), and a retrieval string 26 .
- a metal frame 22 or “shape memory member”
- copper sleeves 24 or “copper elements”
- a retrieval string 26 a retrieval string 26 .
- the shape memory member 22 is generally made of a wire or wire-like material
- the copper sleeves 24 are generally tubular or partially tubular structures.
- the shape memory member 22 and/or the sleeves 24 may take any of a number of different forms.
- the elongate shape memory member 22 may have a two-dimensional (i.e., predominantly flat) configuration, as shown, or may have a more three dimensional (i.e., slightly bent out of plane) configuration.
- the elongate shape memory member 22 may include a loop portion 36 at the bottom (or “vertex”) of the IUD 20 , two generally parallel portions 35 extending vertically upward from the loop portion 36 , multiple twists 34 , a middle portion, two bends 32 that form the shape memory member 22 into two, approximately oppositely directed arms 31 , and two tissue contact surfaces (or “end points”) 28 at the ends of the two arms 31 .
- the copper sleeves 24 are disposed around the shape memory member 22 at multiple locations, such as near each of the tissue contact surfaces 28 , along the arms 31 between the bends 32 and the tissue contact surfaces 28 , and at or near the loop portion 36 . Different numbers and positions of the copper sleeves 24 may be provided in different alternative embodiments.
- the bottom loop portion 36 does not form any turns of a spring structure.
- this embodiment includes twists the 34 between the parallel portions 35 and the middle portion 30 . Twists 34 may be formed when the two portions 35 of the elongate member 22 cross each other more than once in a longitudinally extending helix containing multiple turns that run in series from closer to the loop portion 36 upward, until the arms diverge again from the twisted portion 34 .
- FIG. 3 shows three twists 34 . However, other numbers of twists (e.g., 1-5, 6-10, greater than 10) are also possible. In this embodiment, the twists 34 act as the “spring portion” to confer laterally directed pressure to tissue contact surfaces 28 .
- the anatomical dimensions or characteristics of the uterus or medical conditions of a patient may call for adjustments to the outward force produced by the IUD 20 .
- the location of the twists 34 along the shape memory member 22 , the number of the twists 34 , and/or the tightness of the twists 34 may be used to provide variability in the properties of the device 20 .
- increasing the number of twists 34 may increase the stiffness of the elongate member 22
- decreasing the number of twists 34 may decrease the stiffness of the elongate member 22
- increasing the tightness of the twists 34 may increase the stiffness of the elongate member 22 .
- Decreasing the tightness of the twists 34 may decrease the stiffness of the elongate member 22 .
- Moving the twists 34 upward along the shape memory member 22 may increase the stiffness of the elongate member 22
- moving the twists downward along the shape memory member 22 may decrease the stiffness of the elongate member 22 .
- the variability provided by the twists 34 also allows much easier and more continuous customization of properties by merely modifying the nature of the twists 34 , rather than the thickness or material of the wire used to for the shape memory member 22 itself to produce similar variations in properties. Wires come in standard sizes and materials, and if some intermediate is desired, the expense can make producing such a modified device impractical. Controlling properties of the device with the properties of the twists 34 resolves this issue.
- the galvanic effect can be exploited in the copper IUD 20 by coupling the copper elements 24 to the metal frame 22 or other metal structure.
- the material of the metal frame 22 or other elongate shape memory structure may be chosen to achieve a desired galvanic effect between itself and the copper elements 24 .
- the frame 22 may be made of Nitinol (see FIG. 3 , on which Nitinol and copper are depicted). In other embodiments, however, any of a number of other suitable biocompatible metals (or combinations of metals) may be selected for making the frame 22 .
- the type of material selected for the frame 22 may be specifically selected to provide a particular copper elution rate.
- the type of size, number, positioning, and/or other factors pertaining to the copper sleeves 24 may be specifically selected to provide a particular embodiment with a particular copper elution rate.
- any of a number of characteristics of the frame 22 and/or the sleeves 24 such as but not limited to their materials, may be selected to provide a desired copper elution rate.
- a “baseline” copper ion elution rate may be defined as one in which there is no galvanic effect present (e.g., copper on a polymer frame, as in prior art IUDs). If the metal frame 22 (or other metallic structure) is selected to have a galvanic potential more anodic than the galvanic potential of the copper sleeves 24 (lower on the galvanic series), then the electrochemical driving force would be toward the copper sleeves 24 , thereby reducing the copper ion release rate relative to the baseline.
- the electrochemical driving force would be away from the copper sleeve 24 , thereby increasing the copper ion release rate relative to the baseline.
- the galvanic potential is also related to the relative surface areas of the anode and the cathode, so the surface area ratio between the frame 22 and the copper sleeves 24 may also be selected to achieve a desired ion release rate.
- the material of the frame 22 and/or other elements in contact with the copper elements 24 may be selected to control the galvanic potential between the frame 22 and the copper 24 , thereby allowing specificity, control and optimization of the ion release rate.
- the IUD 20 may achieve a copper release rate comparable or identical to that of a currently available (i.e., prior art) IUD with a lower amount (i.e., less surface area) of copper, by coupling the copper 24 with the metal frame 22 that is more cathodic than the copper 24 .
- the smaller surface area of the copper 24 may help reduce copper-related side effects, compared to prior art copper IUDs.
- the IUD 20 may be configured to release copper ions at a rate similar or identical to that of a currently available copper IUD but for a longer period of time. This may be achieved by giving the copper sleeves 24 a greater exposed surface area than the copper element(s) of a currently available device, while coupling the sleeves 24 with the frame 22 made of a material that is more anodic than the copper elements 24 . In this case, the greater amount of available copper is balanced by a slower release rate to achieve, overall, a similar ion release profile. However, in this case, the slower release rate with a larger copper reservoir allows the elution to happen over a potentially longer period of time, thereby extending the effectiveness of the IUD 20 beyond the typical 10 years of device life.
- the IUD 20 may achieve a copper ion release rate whose release curve is more curvilinear or more linear in comparison to the standard commercial copper IUD release rate curve.
- a metallic IUD with a controlled release rate may be chosen to avoid the burst release of copper ions typically associated with commercial copper IUDs which implement a plastic core.
- the burst release of copper ions has been shown to be directly associated with the onset of clinical side effects of the standard commercial copper IUDs, including in particular, side effects experienced in the first 1 to 6 months of IUD use, including increased menstrual bleeding, intermenstrual bleeding, cramping and general pelvic pain. Such a reduction in clinical side effects without with the need for ancillary medications would be a significant advantage.
- the copper elements 24 may take any suitable shape, size, form and number, according to various embodiments. In the embodiment illustrated in FIG. 3 , there are ten copper sleeves 24 disposed on the frame 22 . Alternative embodiments may include more or fewer sleeves 24 and/or smaller or larger sleeves 24 . In other alternative embodiments, the sleeves 24 may be replaced by, or used in combination with, other copper elements, including but not limited to wire, ribbon, coils, tubes, beads, and the like. Additionally, surface processing of the frame 22 and/or other metallic structure may be tailored to achieve a desired galvanic potential. For example, this may be accomplished through heat treatment, oxidation, electropolishing, passivation, and/or other chemical processing.
- the sleeves 24 may be complete tubes. In these embodiments, the sleeves 24 may be passed onto the frame 22 before the frame 22 is bent and twisted to assume its final shape. Alternatively, each sleeve 24 may be a partial tube, and each may include a slit, for example, so that the sleeves 24 can be placed over the frame 22 after the frame 22 has been formed. In some embodiments, some sleeves 24 may be placed over the frame 22 before it is formed into its final shape, and other sleeves 24 may be placed over the frame 22 after it is shaped.
- Potentiodynamic polarization testing was conducted according to ASTM F2129 on copper sleeves and Nitinol frames made from different starting wires and processed in different ways. This testing was conducted in phosphate buffered saline (PBS) at 37° C. at a pH of 7.1. PBS was chosen for this testing for simplicity as well as to allow comparison of the Nitinol corrosion behavior with data from the literature. The testing was conducted using a Gamry Cyclic Polarization Corrosion Apparatus.
- PBS phosphate buffered saline
- simulated uterine fluid per the following composition: NaHCO3 0.25; NaH2PO4 2H20 0/072; Glucose 0.50; CaCl2 0.167; KCl 0.224; NaCl 4.97.
- the Simulated Uterine Fluid solution was purged with nitrogen gas, and pH was adjusted to 7.1 before testing.
- the Rest Potential (“Er”) was monitored for one hour before the corrosion test began. Specimens were subjected to a scan from below the zero current potential to 1.0 V at a rate of 1 mV/s. No reverse scan was conducted, and the test was stopped after a scan of ⁇ 1 mV/s to 0.8 V (vs. Er).
- the ideal Nitinol surface processing scheme would achieve a rest potential (Erest) that is similar to or higher than that of the copper sleeves ( ⁇ 286.1 mV), in order to both optimize the intentional corrosion (and ion release) of the copper and minimize any deleterious galvanic corrosion effects on the Nitinol frame.
- the Nitinol surface should demonstrate excellent resistance to breakdown. Based on the work of Rosenbloom and Corbett, a Nitinol surface with an average breakdown potential in excess of 600 mV (as tested in PBS at 37° C.) is generally considered to be in an optimum state for use as a medical implant.
- FIGS. 4 - 6 illustrate plots of all the curves for a given sample group on the same axes.
Landscapes
- Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Abstract
Description
- The present application is a continuation of U.S. patent application Ser. No. 15/441,539, entitled, “Intrauterine Device with Controlled Copper Ion Elution,” filed Feb. 24, 2017, which is a continuation-in-part of U.S. patent application Ser. No. 14/289,530, entitled “Intrauterine Device with Controlled Copper Ion Elution,” filed May 28, 2014, now U.S. Pat. No. 10,188,546, which claims priority to U.S. Provisional Patent Application No. 61/890,714, entitled “Intrauterine Device with Controlled Copper Ion Elution,” filed on Oct. 14, 2013. The full disclosures of the above-listed patent applications are hereby incorporated by reference herein.
- The present invention relates to medical devices. More specifically, the invention relates to intrauterine devices for contraception.
- An intrauterine device (IUD) is a small, often T-shaped device, containing copper or hormone (e.g., levonorgestrel), which is inserted into the uterus to provide long-acting, reversible contraception. As of 2007, IUDs are the most widely used form of reversible contraception, with more than 180 million users worldwide. IUDs typically are one of two types—copper or hormonal.
- Copper IUDs primarily work by disrupting sperm motility and damaging sperm so that the sperm are prevented from joining with an egg. Copper acts as a spermicide within the uterus, increasing levels of copper ions, prostaglandins, and white blood cells within the uterine and tubal fluids. The increased copper ions in the cervical mucus inhibit the sperm's motility and viability, preventing sperm from traveling through a thickened cervical mucus and/or destroying it as it passes through. Copper IUDs have a typical first-year contraceptive success rate greater than 98 percent.
- Most copper IUDs have a plastic T-shaped frame that is wound with pure electrolytic copper wire and/or has copper collars (sleeves). The arms of the frame hold the IUD in place near the top of the uterus. The Paragard® intrauterine copper contraceptive device (www.paragard.com) and the generic TCU 380A are currently the most common copper IUDs. Copper IUDs can typically be implanted for up to 10 years.
- The mechanism of action of a copper IUD is essentially a predictable electrochemical process of corrosion, driven by the IUD's immersion in the uterine fluid. Over time, the copper element (wires, beads, tubes, etc.) corrodes and releases copper ions. Typically, the release rate is governed by the surface area and volume of copper, the chemistry (especially pH) of the uterine fluid, and the specific composition and surface properties of the copper elements. The frame of the IUD on which the copper is attached is typically made of a flexible, non-corrosive polymer. Since typical polymers are not electrochemically active, they do not influence the ion release rate of the copper elements. Therefore, the copper ion release characteristics of a typical plastic-frame IUD are strictly governed by the amount, preparation and configuration of the copper itself. One challenge with copper IUDs has been that increased effectiveness typically means increased amounts of copper on the IUD, and increased amounts of copper typically lead to increased side effects, primarily increased menstrual and intermenstrual bleeding, and increased pelvic pain. Balancing effectiveness with minimization of side effects has been a continuing challenge for making copper IUDs.
- One advantage of the copper IUD is its ability to provide emergency contraception up to five days after unprotected sex. It is generally known as the most effective form of emergency contraception available. Another advantage is that it contains no hormones, so it can be used while breast feeding, and fertility returns quickly after removal. Lastly, copper IUDs have been shown to be clinically effective for up to 10 years of continuous use. Disadvantages include the possibility of heavier menstrual periods and more painful menstrual cramping in some women.
- A hormonal IUD, such as the Mirena® Levonorgestrel-releasing intrauterine system (www.mirena-us.com), uses the controlled release of a hormonal contraceptive such as Levonorgestrel (a progestin). The hormonal contraceptive released from a hormonal IUD prevents ovulation from occurring. The hormone also thickens the cervical mucus so that sperm cannot reach the fallopian tubes. Hormonal IUDs can typically be implanted for up to 5 years.
- Hormonal IUDs do not increase bleeding as copper-containing IUDs do. Instead, they can often reduce menstrual bleeding or prevent menstruation altogether, and thus they are sometimes used as a treatment for menorrhagia (heavy menstrual bleeding). Hormonal IUDs have common side effects, however. The most common side effects with levonorgestrel IUDs are hormone-related effects, such as headaches, nausea, breast tenderness, depression and cyst formation.
- Based on effectiveness and the types of side effects, copper IUDs are preferable for many women. Although currently available copper IUDs are very effective, it would still be advantageous to have improved copper IUDs. For example, it would be advantageous to have copper IUDs that were very effective but had minimal side effects.
- Disclosed herein are various embodiments of an improved copper IUD. Generally, the described embodiments provide an IUD with a desirable (or “controlled”) release rate of copper ions. Different embodiments may be configured with different copper ion release rates. For example, a particular copper ion release rate may be identified to provide a desired balance between IUD effectiveness and reduced side effects, compared to currently available devices.
- In one aspect of the present application, an intrauterine contraceptive device may include a frame comprising a first metal having a first galvanic potential and at least one metallic member coupled with the frame, the at least one metallic member comprising a second metal having a second galvanic potential different from the first galvanic potential. In some embodiments, the first galvanic potential may be more anodic than the second galvanic potential. In alternative embodiments, the first galvanic potential may be more cathodic than the second galvanic potential.
- In some embodiments, the frame may be made entirely of metal. Alternatively, the frame may be made partially of metal and partially of a non-metallic substance. For example, the first metal may in some embodiments be Nitinol. The second metal may be copper. In some embodiments, for example, the metallic members are multiple copper sleeves disposed around the frame at various locations. Some embodiments include the combination of the first metal being Nitinol and the second metal being copper. In embodiments where the second metal is copper, the first galvanic potential and the second galvanic potential may be configured to achieve approximately a desired copper elution rate of the at least one metallic member. In all of these embodiments, the non-metallic substance may be a polymer, a silicone rubber or other engineered polymer plastic, for example. Optionally, the device may further include a retrieval string attached to one end of the metal frame.
- In another aspect of this disclosure, a method of preventing conception may involve advancing an intrauterine contraceptive device into a uterus, where the intrauterine device includes a frame comprising a first metal having a first galvanic potential, and at least one metallic member coupled with the frame, comprising a second metal having a second galvanic potential different from the first galvanic potential. In some embodiments, the second metal may be copper, and the first and second galvanic potentials may be configured to achieve approximately a desired copper ion elution rate. In some embodiments, the first metal may be Nitinol, and advancing the contraceptive device into the uterus may involve advancing a distal end of an introducer device through a cervix, into the uterus, and advancing the contraceptive device out of the distal end, thus allowing the Nitinol of the frame to expand to contact a wall of the uterus.
- In yet another aspect of the disclosure, a method of manufacturing an IUD for contraception that has a desired copper elution rate may involve: selecting an elongate shape memory member comprising a first metal having a first galvanic potential; selecting at least one attachment member comprising a second metal having a second galvanic potential that is different from the first galvanic potential; attaching the attachment member(s) to the shape memory member; and shaping the shape memory member to form a frame of the intrauterine contraceptive device. The first metal and the second metal may be specifically selected as materials for the shape memory member and the at least one attachment member, in order to achieve the desired copper elution rate.
- In some embodiments, the shape memory member may be a wire. Merely by way of example, the first material may be Nitinol, stainless steel, titanium, cobalt-based alloys, tantalum, platinum, gold, silver, or MP35N. In one embodiment, for example, the first metal is Nitinol, and the second metal is copper. Some embodiments may include multiple copper sleeves, which may be attached to the frame, for example, by passing the multiple copper sleeves over the shape memory member. In such an embodiment, the method may also include positioning the multiple sleeves along the shape memory member at different positions before or after shaping the shape memory member. The attachment member(s) may have any of a number of different forms, such as but not limited to sleeves, wires, ribbons, coils, tubes and beads.
- In some embodiments, the first galvanic potential is more anodic than the second galvanic potential. Alternatively, the first galvanic potential may be more cathodic than the second galvanic potential. In some embodiments, the frame is made entirely of the first metal. In other embodiments, the frame is made partially of the first metal and partially of a non-metallic substance. For example, the frame may include a non-rigid material, such as but not limited to a flexible polymer thread, a polyester thread, a nylon thread or other biocompatible fabric. Optionally, the method may also include attaching a retrieval string to a bottom portion of the frame.
- In one embodiments, shaping the shape memory member may involve forming the frame to include: a bottom loop; a middle portion comprising two parts of the elongate shape memory member extending upward from the bottom loop; multiple twists in the middle portion, forming a spring portion; two bends in the elongate shape memory member at a location above the multiple twists, where the elongate member crosses over itself; a first arm extending from a first bend of the two bends; a second arm extending from a second bend of the two bends; a first end loop at an end of the first arm; and a second end loop at an end of the second arm, where the first end loop and the second end loop in the elongate shape memory member comprise tissue contact surfaces.
- In another aspect of this application, a method of manufacturing an IUD for contraception that has a desired copper elution rate may involve: selecting a wire comprising a first metal having a first galvanic potential; selecting at least one attachment member comprising a second metal having a second galvanic potential that is different from the first galvanic potential; attaching the at least one attachment member to the wire; and shaping the wire to form a frame. The shaping step may result in a frame that has: a bottom loop; a middle portion; multiple twists in the middle portion; two bends in the elongate shape memory member at a location above the multiple twists in the middle portion, where the elongate member crosses over itself; two arms extending from the two bends; a first end loop at an end of one of the two arms; and a second end loop at an end of the other of the two arms.
- These and other aspects and embodiments will be described in further detail below, in reference to the attached drawing figures.
-
FIG. 1 is a front view of a prior art, T-shaped, copper IUD with a plastic support structure; -
FIG. 2 is a bar graph illustrating a galvanic series for a number of common metals and alloys; -
FIG. 3 is a front view of a copper IUD with a metal frame, according to one embodiment; -
FIG. 4 illustrates potentiodynamic polarization curves for copper sleeves tested in simulated uterine fluid at 37° C., pH=7.1; -
FIG. 5 illustrates potentiodynamic polarization curves for bare Nitinol frames tested in simulated uterine fluid at 37° C., pH=7.1; and -
FIG. 6 illustrates potentiodynamic polarization curves for finished device assemblies (copper sleeves crimped onto Nitinol frames) tested in simulated uterine fluid at 37° C., pH=7.1. - The mechanism of action of a copper IUD is essentially a predictable electrochemical process of corrosion, driven by the IUD's immersion in the uterine fluid. Over time, the copper elements of the IUD (copper wires, beads, tubes, or the like) corrode and release copper ions. For a given IUD, the copper ion release rate can be measured using standard laboratory tests in simulated uterine fluid (SUF). Typically, the release rate is governed by the surface area and volume of copper, the chemistry (especially pH) of the SUF, and the specific composition and surface properties of the copper elements. In currently available IUDs, the primary driver influencing the copper release rate is the amount of exposed copper surface area. In other words, to achieve a higher copper ion release rate, an IUD would typically have an increased copper surface area, which generally means the IUD will contain more copper overall.
- Referring now to
FIG. 1 , a typical, prior art, T-shaped,copper IUD 10 is illustrated. TheIUD 10 includes aframe 12,copper sleeves 14 disposed around theframe 12 in three areas, and aretrieval string 16. Theframe 12 is typically made of a flexible polymer and is often T-shaped for positioning in the uterus. Since typical polymers are not electrochemically active, they do not influence the ion release rate of thecopper elements 14. Therefore, the copper ion release characteristics are strictly governed by the amount of surface area of thecopper sleeves 14 themselves. - Galvanic corrosion is an electrochemical process in which one metal corrodes preferentially to another when both metals are in electrical contact and immersed in an electrolyte. The strength of this electrical potential between two metals or alloys is called the galvanic potential. The galvanic reaction can be exploited for positive benefit. For example, a galvanic potential between dissimilar metals can be used in primary batteries to generate an electrical voltage. The measured voltage is representative of the transfer of charged metal ions from one of the metals (the anode) to the other (the cathode). The stronger the galvanic effect between the two metals, the higher the transfer rate of ions from the anode to the cathode.
- To determine the galvanic potential between two metals, we use a galvanic series, an example of which is illustrated in
FIG. 2 . In a galvanic series, metals are ranked by the electrical potential they develop in a given electrolyte against a standard reference electrode— i.e., their galvanic potential versus the reference electrode. The relative position of two metals on such a series determines which metal will be the anode and which will be the cathode (if they are put in contact in an appropriate electrolyte). The magnitude of the distance between the two metals on the galvanic series will determine the strength of the galvanic potential between them. A specific galvanic series can be determined for any metals or alloys of interest, tested in a specific electrolyte (e.g., SUF) at an appropriate pH. - Referring now to
FIG. 3 , in one embodiment, anIUD 20 may include a metal frame 22 (or “shape memory member”), multiple copper sleeves 24 (or “copper elements”), and aretrieval string 26. This embodiment of theIUD 20, as well as other, alternative embodiments, is described in further detail in pending U.S. patent application Ser. No. 13/795,940, entitled “Intrauterine Contraceptive Device,” filed Mar. 12, 2013, which is hereby incorporated by reference in its entirety. In this embodiment, theshape memory member 22 is generally made of a wire or wire-like material, and thecopper sleeves 24 are generally tubular or partially tubular structures. In alternative embodiments, however, theshape memory member 22 and/or thesleeves 24 may take any of a number of different forms. For example, in one embodiment, theshape memory member 22 may be configured more like a flat ribbon that a cylindrical wire. In other embodiments, thesleeves 24 may be replaced by any other suitable attachment members, such as balls, coatings, clamps, tape or the like. Thus, thesleeves 24 are merely one example of a type of attachment member that might be used in forming theIUD 20. - In various embodiments, the elongate
shape memory member 22 may have a two-dimensional (i.e., predominantly flat) configuration, as shown, or may have a more three dimensional (i.e., slightly bent out of plane) configuration. The elongateshape memory member 22 may include aloop portion 36 at the bottom (or “vertex”) of theIUD 20, two generallyparallel portions 35 extending vertically upward from theloop portion 36,multiple twists 34, a middle portion, two bends 32 that form theshape memory member 22 into two, approximately oppositely directedarms 31, and two tissue contact surfaces (or “end points”) 28 at the ends of the twoarms 31. Thecopper sleeves 24 are disposed around theshape memory member 22 at multiple locations, such as near each of the tissue contact surfaces 28, along thearms 31 between the bends 32 and the tissue contact surfaces 28, and at or near theloop portion 36. Different numbers and positions of thecopper sleeves 24 may be provided in different alternative embodiments. - In this embodiment, the
bottom loop portion 36 does not form any turns of a spring structure. Instead, to generate resilience in thearms 31 of theIUS 20, this embodiment includes twists the 34 between theparallel portions 35 and themiddle portion 30.Twists 34 may be formed when the twoportions 35 of theelongate member 22 cross each other more than once in a longitudinally extending helix containing multiple turns that run in series from closer to theloop portion 36 upward, until the arms diverge again from the twistedportion 34.FIG. 3 shows threetwists 34. However, other numbers of twists (e.g., 1-5, 6-10, greater than 10) are also possible. In this embodiment, thetwists 34 act as the “spring portion” to confer laterally directed pressure to tissue contact surfaces 28. - It may be desirable to be able to easily modify the properties of the
elongate member 22. For example, the anatomical dimensions or characteristics of the uterus or medical conditions of a patient may call for adjustments to the outward force produced by theIUD 20. In such applications, the location of thetwists 34 along theshape memory member 22, the number of thetwists 34, and/or the tightness of thetwists 34 may be used to provide variability in the properties of thedevice 20. For example, increasing the number oftwists 34 may increase the stiffness of theelongate member 22, and decreasing the number oftwists 34 may decrease the stiffness of theelongate member 22. For another example, increasing the tightness of thetwists 34 may increase the stiffness of theelongate member 22. Decreasing the tightness of thetwists 34 may decrease the stiffness of theelongate member 22. Moving thetwists 34 upward along theshape memory member 22 may increase the stiffness of theelongate member 22, and moving the twists downward along theshape memory member 22 may decrease the stiffness of theelongate member 22. With the device ofFIG. 3 , a variety of differently configured devices can be made available to physicians to apply in the appropriate circumstances. The variability provided by thetwists 34 also allows much easier and more continuous customization of properties by merely modifying the nature of thetwists 34, rather than the thickness or material of the wire used to for theshape memory member 22 itself to produce similar variations in properties. Wires come in standard sizes and materials, and if some intermediate is desired, the expense can make producing such a modified device impractical. Controlling properties of the device with the properties of thetwists 34 resolves this issue. - According to various embodiments, the galvanic effect can be exploited in the
copper IUD 20 by coupling thecopper elements 24 to themetal frame 22 or other metal structure. The material of themetal frame 22 or other elongate shape memory structure may be chosen to achieve a desired galvanic effect between itself and thecopper elements 24. In one embodiment, for example, theframe 22 may be made of Nitinol (seeFIG. 3 , on which Nitinol and copper are depicted). In other embodiments, however, any of a number of other suitable biocompatible metals (or combinations of metals) may be selected for making theframe 22. In various embodiments, the type of material selected for theframe 22, the characteristics of the material (thickness, for example), the overall size of the IUD 20 (and thus the amount of the material used to make the frame 22), and/or other characteristics of theframe 22 may be specifically selected to provide a particular copper elution rate. Similarly, the type of size, number, positioning, and/or other factors pertaining to thecopper sleeves 24 may be specifically selected to provide a particular embodiment with a particular copper elution rate. In other words, any of a number of characteristics of theframe 22 and/or thesleeves 24, such as but not limited to their materials, may be selected to provide a desired copper elution rate. - For the sake of comparison, a “baseline” copper ion elution rate may be defined as one in which there is no galvanic effect present (e.g., copper on a polymer frame, as in prior art IUDs). If the metal frame 22 (or other metallic structure) is selected to have a galvanic potential more anodic than the galvanic potential of the copper sleeves 24 (lower on the galvanic series), then the electrochemical driving force would be toward the
copper sleeves 24, thereby reducing the copper ion release rate relative to the baseline. Alternatively, if themetal frame 22 or structure that has a galvanic potential more cathodic than the copper sleeves 24 (higher on the galvanic series), then the electrochemical driving force would be away from thecopper sleeve 24, thereby increasing the copper ion release rate relative to the baseline. The greater the difference between the materials on the galvanic series, the more significant the decrease or increase in copper ion release rate. The galvanic potential is also related to the relative surface areas of the anode and the cathode, so the surface area ratio between theframe 22 and thecopper sleeves 24 may also be selected to achieve a desired ion release rate. - In such a way, the material of the
frame 22 and/or other elements in contact with thecopper elements 24 may be selected to control the galvanic potential between theframe 22 and thecopper 24, thereby allowing specificity, control and optimization of the ion release rate. This may have a number of advantages. In some embodiments, theIUD 20 may achieve a copper release rate comparable or identical to that of a currently available (i.e., prior art) IUD with a lower amount (i.e., less surface area) of copper, by coupling thecopper 24 with themetal frame 22 that is more cathodic than thecopper 24. The smaller surface area of thecopper 24 may help reduce copper-related side effects, compared to prior art copper IUDs. Alternatively, in other embodiments, theIUD 20 may be configured to release copper ions at a rate similar or identical to that of a currently available copper IUD but for a longer period of time. This may be achieved by giving the copper sleeves 24 a greater exposed surface area than the copper element(s) of a currently available device, while coupling thesleeves 24 with theframe 22 made of a material that is more anodic than thecopper elements 24. In this case, the greater amount of available copper is balanced by a slower release rate to achieve, overall, a similar ion release profile. However, in this case, the slower release rate with a larger copper reservoir allows the elution to happen over a potentially longer period of time, thereby extending the effectiveness of theIUD 20 beyond the typical 10 years of device life. - In still other embodiments, the
IUD 20 may achieve a copper ion release rate whose release curve is more curvilinear or more linear in comparison to the standard commercial copper IUD release rate curve. In this manner, a metallic IUD with a controlled release rate may be chosen to avoid the burst release of copper ions typically associated with commercial copper IUDs which implement a plastic core. The burst release of copper ions has been shown to be directly associated with the onset of clinical side effects of the standard commercial copper IUDs, including in particular, side effects experienced in the first 1 to 6 months of IUD use, including increased menstrual bleeding, intermenstrual bleeding, cramping and general pelvic pain. Such a reduction in clinical side effects without with the need for ancillary medications would be a significant advantage. - In various embodiments, a method for making the
IUD 20 may first involve selecting the wire material for making themetal frame 22 and selecting (or perhaps manufacturing) thecopper sleeves 24. Themetal frame 22 and/or any other metal structure(s) onIUD 20 may be made from any material with desired galvanic properties, including but not limited to Nitinol, stainless steel, titanium, cobalt-based alloys, tantalum, platinum, gold, silver, and MP35N. Theframe 22 may be made from one material or multiple materials. In alternative embodiments, theframe 22 may be made entirely of metal or may have discrete active metallic portions or elements, some or all of which may be in contact with thecopper elements 24, with non-metallic parts between the metallic portions or with no parts at all between the metallic portions. Thecopper elements 24 may take any suitable shape, size, form and number, according to various embodiments. In the embodiment illustrated inFIG. 3 , there are tencopper sleeves 24 disposed on theframe 22. Alternative embodiments may include more orfewer sleeves 24 and/or smaller orlarger sleeves 24. In other alternative embodiments, thesleeves 24 may be replaced by, or used in combination with, other copper elements, including but not limited to wire, ribbon, coils, tubes, beads, and the like. Additionally, surface processing of theframe 22 and/or other metallic structure may be tailored to achieve a desired galvanic potential. For example, this may be accomplished through heat treatment, oxidation, electropolishing, passivation, and/or other chemical processing. - In some embodiments, the
sleeves 24 may be complete tubes. In these embodiments, thesleeves 24 may be passed onto theframe 22 before theframe 22 is bent and twisted to assume its final shape. Alternatively, eachsleeve 24 may be a partial tube, and each may include a slit, for example, so that thesleeves 24 can be placed over theframe 22 after theframe 22 has been formed. In some embodiments, somesleeves 24 may be placed over theframe 22 before it is formed into its final shape, andother sleeves 24 may be placed over theframe 22 after it is shaped. - To determine the baseline corrosion behavior of a Nitinol frame and copper sleeves, such as those described above in reference to
FIG. 3 (together referred to below as the “ContraMed IUD”), and to evaluate the effects of different surface processing on the Nitinol frame, preliminary potentiodynamic polarization testing was conducted. Processing of the Nitinol surface was targeted to achieve a rest potential (“Erest”) similar to or higher than that of the copper sleeves, in order to both optimize the intentional corrosion (and ion release) of the copper and minimize any deleterious galvanic corrosion effects on the Nitinol frame. A review of the literature of electropolished, etched, chemically-polished, and heat-treated (with oxide) Nitinol revealed that rest potentials can be of a wide range, from less than −420 mV to as high as +20 mV vs. SCE. - Potentiodynamic polarization testing was conducted according to ASTM F2129 on copper sleeves and Nitinol frames made from different starting wires and processed in different ways. This testing was conducted in phosphate buffered saline (PBS) at 37° C. at a pH of 7.1. PBS was chosen for this testing for simplicity as well as to allow comparison of the Nitinol corrosion behavior with data from the literature. The testing was conducted using a Gamry Cyclic Polarization Corrosion Apparatus.
- Testing was also conducted in simulated uterine fluid (SUF) per the following composition: NaHCO3 0.25;
NaH2PO4 2H20 0/072; Glucose 0.50; CaCl2 0.167; KCl 0.224; NaCl 4.97. The Simulated Uterine Fluid solution was purged with nitrogen gas, and pH was adjusted to 7.1 before testing. The Rest Potential (“Er”) was monitored for one hour before the corrosion test began. Specimens were subjected to a scan from below the zero current potential to 1.0 V at a rate of 1 mV/s. No reverse scan was conducted, and the test was stopped after a scan of −1 mV/s to 0.8 V (vs. Er). - As described previously, the ideal Nitinol surface processing scheme would achieve a rest potential (Erest) that is similar to or higher than that of the copper sleeves (−286.1 mV), in order to both optimize the intentional corrosion (and ion release) of the copper and minimize any deleterious galvanic corrosion effects on the Nitinol frame. At the same time, the Nitinol surface should demonstrate excellent resistance to breakdown. Based on the work of Rosenbloom and Corbett, a Nitinol surface with an average breakdown potential in excess of 600 mV (as tested in PBS at 37° C.) is generally considered to be in an optimum state for use as a medical implant.
-
FIGS. 4-6 illustrate plots of all the curves for a given sample group on the same axes.FIG. 4 illustrates potentiodynamic polarization curves for copper sleeves tested in simulated uterine fluid at 37° C., pH=7.1.FIG. 5 illustrates potentiodynamic polarization curves for bare Nitinol frames tested in simulated uterine fluid at 37° C., pH=7.1.FIG. 6 illustrates potentiodynamic polarization curves for finished device assemblies (copper sleeves crimped onto Nitinol frames) tested in simulated uterine fluid at 37° C., pH=7.1. As illustrated inFIGS. 4-6 , the copper curves and the Nitinol curves are very different. Copper corrodes via generalized corrosion, while Nitinol, due to its formation of a protective surface oxide layer, corrodes via breakdown (i.e., pitting). As expected, the corrosion of the assembled devices is dominated by corrosion of the copper sleeves, and no breakdown behavior is observed in the potentiodynamic polarization curve. - Although various embodiments and features are described herein, the present invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. Thus, the scope of the present invention herein disclosed should not be limited by the particular disclosed embodiments described above.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/158,149 US20230157863A1 (en) | 2013-10-14 | 2023-01-23 | Intrauterine device with controlled copper ion elution |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361890714P | 2013-10-14 | 2013-10-14 | |
US14/289,530 US10188546B2 (en) | 2013-10-14 | 2014-05-28 | Intrauterine device with controlled copper ion elution |
US15/441,539 US10918516B2 (en) | 2013-10-14 | 2017-02-24 | Intrauterine device with controlled copper ion elution |
US17/175,319 US20210161703A1 (en) | 2013-10-14 | 2021-02-12 | Intrauterine device with controlled copper ion elution |
US18/158,149 US20230157863A1 (en) | 2013-10-14 | 2023-01-23 | Intrauterine device with controlled copper ion elution |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/175,319 Continuation US20210161703A1 (en) | 2013-10-14 | 2021-02-12 | Intrauterine device with controlled copper ion elution |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230157863A1 true US20230157863A1 (en) | 2023-05-25 |
Family
ID=59018357
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/441,539 Active 2037-01-23 US10918516B2 (en) | 2013-10-14 | 2017-02-24 | Intrauterine device with controlled copper ion elution |
US17/175,319 Abandoned US20210161703A1 (en) | 2013-10-14 | 2021-02-12 | Intrauterine device with controlled copper ion elution |
US18/158,149 Pending US20230157863A1 (en) | 2013-10-14 | 2023-01-23 | Intrauterine device with controlled copper ion elution |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/441,539 Active 2037-01-23 US10918516B2 (en) | 2013-10-14 | 2017-02-24 | Intrauterine device with controlled copper ion elution |
US17/175,319 Abandoned US20210161703A1 (en) | 2013-10-14 | 2021-02-12 | Intrauterine device with controlled copper ion elution |
Country Status (1)
Country | Link |
---|---|
US (3) | US10918516B2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9089418B2 (en) | 2012-08-14 | 2015-07-28 | Contramed, Llc | Intrauterine contraceptive device |
US9265652B2 (en) | 2012-08-14 | 2016-02-23 | Contramed, Llc | Intrauterine contraceptive device |
US10188546B2 (en) | 2013-10-14 | 2019-01-29 | Sebela Vlc Limited | Intrauterine device with controlled copper ion elution |
US10918516B2 (en) * | 2013-10-14 | 2021-02-16 | Sebela Vlc Limited | Intrauterine device with controlled copper ion elution |
US9180040B2 (en) | 2013-10-18 | 2015-11-10 | Contramed, Llc | Intrauterine device with retrieval thread |
CN112972061A (en) * | 2021-02-04 | 2021-06-18 | 胡军 | Novel anti-infection periosteum stretching device and application |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US662716A (en) | 1900-07-31 | 1900-11-27 | John G L Gaedeke | Intra-uterine battery. |
US3407806A (en) | 1966-08-24 | 1968-10-29 | Butler Automatic Machine Inc | Contraceptive intra-uterine devices |
US3492990A (en) | 1967-06-15 | 1970-02-03 | Robert E Clarke | Combination contraceptive device and inserter |
US3678927A (en) | 1968-03-18 | 1972-07-25 | Samuel Soichet | Intra uterine device and injector thereof |
US3911911A (en) | 1969-06-16 | 1975-10-14 | Reese Hospital Michael | Anti-fertility device |
NL6915483A (en) | 1969-10-14 | 1971-04-16 | ||
US3789838A (en) | 1971-02-19 | 1974-02-05 | E Fournier | Force transmitting intrauterine device |
BE791735A (en) | 1971-06-23 | 1973-03-16 | Robins Co Inc A H | ELEMENT OF INTRA-UTERINE TREATMENT |
US3996933A (en) | 1972-10-02 | 1976-12-14 | Morton Gutnick | Intrauterine contraceptive devices and processes |
GB1465684A (en) | 1973-07-27 | 1977-02-23 | Emmett L | Contraceptive device |
US3902483A (en) | 1974-08-21 | 1975-09-02 | Alza Corp | Intrauterine device with locator means for indicating uterine position of device |
US4136695A (en) | 1975-07-09 | 1979-01-30 | Gynetech-Denver, Inc. | Transvaginal sterilization instrument |
FR2435943A1 (en) | 1978-09-12 | 1980-04-11 | Berre N Le | COLORIMETRIC GRADUATION SYSTEM FOR IDENTIFYING THE PLACE OF AN INTRA-UTERINE DEVICE |
US4762130A (en) | 1987-01-15 | 1988-08-09 | Thomas J. Fogarty | Catheter with corkscrew-like balloon |
CN87210467U (en) | 1987-08-19 | 1988-04-06 | 大连市计划生育研究所 | Butterfly-shape intrauterine device used in uterus |
HU200905B (en) | 1989-02-07 | 1990-09-28 | Radelkis Electrokemiai | Electrochemical contraceptive device |
US5370129A (en) | 1992-08-28 | 1994-12-06 | Db Inserters, Inc. | IUD inserting apparatus |
US5368564A (en) | 1992-12-23 | 1994-11-29 | Angeion Corporation | Steerable catheter |
FI97946C (en) | 1994-12-15 | 1997-03-25 | Leiras Oy | An applicator for inserting an intrauterine device |
US6176240B1 (en) | 1995-06-07 | 2001-01-23 | Conceptus, Inc. | Contraceptive transcervical fallopian tube occlusion devices and their delivery |
US6119696A (en) | 1996-04-22 | 2000-09-19 | Turin; Enrique Horacio | Intrauterine device for use as a contraceptive means in female dogs and methods of insertion thereof |
US6152943A (en) | 1998-08-14 | 2000-11-28 | Incept Llc | Methods and apparatus for intraluminal deposition of hydrogels |
BE1012613A3 (en) | 1999-04-16 | 2001-01-09 | Wildemeersch Dirk | PROCESS FOR RESTRAINT AND OPERATING A IUD inserter, inserter AND FOR THE APPLICATION OF THE METHOD. |
BE1012671A3 (en) | 1999-05-07 | 2001-02-06 | Wildemeersch Dirk | Intra-uterine device increased efficiency and reduced side effects. |
US6709667B1 (en) | 1999-08-23 | 2004-03-23 | Conceptus, Inc. | Deployment actuation system for intrafallopian contraception |
FI119719B (en) | 2003-11-19 | 2009-02-27 | Bayer Schering Pharma Oy | pusher |
US8048086B2 (en) | 2004-02-25 | 2011-11-01 | Femasys Inc. | Methods and devices for conduit occlusion |
US20050240211A1 (en) | 2004-04-21 | 2005-10-27 | Stefan Sporri | Apparatus and method for selectably treating a fallopian tube |
US7699056B2 (en) | 2004-06-10 | 2010-04-20 | Conceptus, Inc. | Medical devices and methods of making and using such devices |
WO2006042561A2 (en) | 2004-10-20 | 2006-04-27 | Mohamed Ezz El Din Azzam | Intrauterine contraceptive system with copper and progesterone |
US8181653B2 (en) | 2005-02-15 | 2012-05-22 | Yale University | Intrauterine fallopian tube occlusion device |
US8662081B2 (en) | 2005-02-15 | 2014-03-04 | Yale University | Intrauterine device |
MX2007009376A (en) | 2005-02-15 | 2008-03-06 | Univ Yale | Intrauterine fallopian tube occlusion device and method for use. |
US20070270942A1 (en) | 2006-05-19 | 2007-11-22 | Medtronic Vascular, Inc. | Galvanic Corrosion Methods and Devices for Fixation of Stent Grafts |
US7774039B2 (en) | 2006-09-05 | 2010-08-10 | Boston Scientific Scimed, Inc. | Multi-bend steerable mapping catheter |
EP1902693A1 (en) * | 2006-09-20 | 2008-03-26 | Melinda-Kinga Karpati | Intrauterine contraceptive device |
US8840626B2 (en) | 2006-10-18 | 2014-09-23 | Hologic, Inc. | Systems for performing gynecological procedures with simultaneous tissue cutting and removal |
US20080216842A1 (en) | 2008-02-19 | 2008-09-11 | Guillermo Sanders Acedo | Contraceptive device designed for mexican women according to the dimensions of their uterine cavity acoording to their parity |
PT2349143E (en) | 2008-09-17 | 2013-07-08 | Bayer Oy | An inserter |
FI20080524A0 (en) | 2008-09-17 | 2008-09-17 | Bayer Schering Pharma Oy | An inserter |
FI20080523A0 (en) | 2008-09-17 | 2008-09-17 | Bayer Schering Pharma Oy | An inserter |
US20100087798A1 (en) | 2008-09-24 | 2010-04-08 | Interlace Medical, Inc. | Systems, methods and devices for using a flowable medium for distending a hollow organ |
US20110061659A1 (en) | 2009-09-17 | 2011-03-17 | Julian Cruzada | Minimally invasive delivery devices and methods |
EP2327382B1 (en) | 2009-11-26 | 2012-07-18 | Hans I. Wallsten | Sterilisation device |
US20120318276A1 (en) * | 2009-12-21 | 2012-12-20 | Pat&Co Bvba | Frameless intrauterine devices and systems |
US8435205B2 (en) | 2010-01-29 | 2013-05-07 | The Procter & Gamble Company | Applicator having a color gradient |
US8573222B2 (en) | 2010-03-21 | 2013-11-05 | David Weintraub | Intrauterine device and inserter for the same |
US9180039B2 (en) | 2010-08-16 | 2015-11-10 | Yale University | Intrauterine device |
US9949870B2 (en) | 2010-10-29 | 2018-04-24 | Odyssea Pharma S.P.R.L. | Intra-uterine insertion device |
FI122579B (en) | 2010-10-29 | 2012-03-30 | Bayer Oy | inserter |
CN202096333U (en) | 2011-04-26 | 2012-01-04 | 张煦喆 | In utero active contraceptive device for animal |
US10028858B2 (en) | 2011-07-11 | 2018-07-24 | Medicines360 | Intrauterine systems, IUD insertion devices, and related methods and kits therefor |
US9265651B2 (en) | 2011-09-19 | 2016-02-23 | Pregna International Limited | Loading, inserting and releasing tool for an intrauterine device |
US20130211321A1 (en) | 2012-02-10 | 2013-08-15 | Laurimed, Llc | Devices and methods for resecting soft tissue |
US20140041667A1 (en) | 2012-08-07 | 2014-02-13 | Scott Cammack | Intra Uterine Device For An Animal And A System For Loading The Intra Uterine Device Into A Delivery Gun |
US9089418B2 (en) | 2012-08-14 | 2015-07-28 | Contramed, Llc | Intrauterine contraceptive device |
US9265652B2 (en) | 2012-08-14 | 2016-02-23 | Contramed, Llc | Intrauterine contraceptive device |
CN203138640U (en) | 2013-01-22 | 2013-08-21 | 徐中华 | Recanalization assembly for fallopian tube |
US10188546B2 (en) | 2013-10-14 | 2019-01-29 | Sebela Vlc Limited | Intrauterine device with controlled copper ion elution |
US10918516B2 (en) * | 2013-10-14 | 2021-02-16 | Sebela Vlc Limited | Intrauterine device with controlled copper ion elution |
US9180040B2 (en) | 2013-10-18 | 2015-11-10 | Contramed, Llc | Intrauterine device with retrieval thread |
CN203970514U (en) | 2014-07-28 | 2014-12-03 | 姚芳 | Haustorium is scraped in blockage resisting uterus |
US20170056237A1 (en) | 2015-09-01 | 2017-03-02 | Contramed, Llc | System and method for fallopian tube occlusion |
-
2017
- 2017-02-24 US US15/441,539 patent/US10918516B2/en active Active
-
2021
- 2021-02-12 US US17/175,319 patent/US20210161703A1/en not_active Abandoned
-
2023
- 2023-01-23 US US18/158,149 patent/US20230157863A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US10918516B2 (en) | 2021-02-16 |
US20170165103A1 (en) | 2017-06-15 |
US20210161703A1 (en) | 2021-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230157863A1 (en) | Intrauterine device with controlled copper ion elution | |
CA2926210C (en) | Intrauterine device with controlled copper ion elution | |
JP5443986B2 (en) | Intrauterine device | |
US10932943B2 (en) | Intrauterine contraceptive device | |
US3378010A (en) | Surgical clip with means for releasing the clamping pressure | |
ES2499566T3 (en) | Implant insertion device | |
JP2006314809A (en) | Blocking device in uterine tube for contraception and its device | |
EP3229745B1 (en) | Device positionable in the uterine cavity | |
EP2515806B1 (en) | Improvements to frameless intrauterine devices and systems | |
WO2011080164A1 (en) | Improvements to frameless intrauterine devices and systems | |
WO1990009158A1 (en) | Intrauterine contraceptive device | |
WO2010112095A1 (en) | Improvement to intrauterine copper contraceptive devices | |
US9907691B2 (en) | Intrauterine contraceptive devices | |
JP2004135905A (en) | Urethra stent | |
CN2465684Y (en) | Intrauterine device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CONTRAMED, LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAL, MICHAEL;KATZ, BOB H.;RUSSELL, SCOTT M.;REEL/FRAME:062454/0445 Effective date: 20170221 Owner name: SEBELA VLC LIMITED, BERMUDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONTRAMED, LLC;REEL/FRAME:062454/0592 Effective date: 20180601 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |